文献速递肿瘤 PET/CT骨显像与常规 SPECT

新诊断多发性骨髓瘤患者18F-FDG PET生物标志物的分子特征:CASSIOPET研究全基因组转录组分析

Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study.
PubMed 文献 · J Nucl Med · 2022-01-27

国际骨髓瘤工作组已将18F-FDG PET纳入多发性骨髓瘤诊断和疗效评估,但PET生物标志物的分子基础尚待阐明。本研究对CASSIOPET队列139例新诊断患者基线18F-FDG PET提取的预后生物标志物与骨髓浆细胞RNA测序转录组进行关联分析,发现PET阴性者HK2表达较低(倍数变化2.1,校正P=0.04),PET阳性者呈现增殖基因高表达或GLUT5及淋巴细胞抗原高表达两种不同特征;旁髓病变与IFM15高危签名独立关联无进展生存期降低,两者并存定义极高进展风险的双阳性组。

要点

  • 139例新诊断多发性骨髓瘤患者中18F-FDG PET阳性率为79.4%,旁髓病变和髓外病变分别占14%和11%。
  • PET阴性结果与己糖激酶2(HK2)表达较低相关(倍数变化2.1,校正P=0.04),并富集低骨病负荷患者亚组。
  • 旁髓病变与IFM15高危签名独立关联无进展生存期降低,两者并存患者进展风险极高。

核心结论

  • 本研究证实并拓展了多发性骨髓瘤影像生物标志物与转录组程序之间的关联。
  • 旁髓病变与IFM15高危签名联合的预后价值可能有助于界定进展风险极高的多发性骨髓瘤患者。

研究设计与样本

  • CASSIOPET研究为CASSIOPEIA队列(ClinicalTrials.gov标识NCT02541383)的伴随研究,纳入139例患者。
  • 从基线18F-FDG PET提取已报道的预后生物标志物:18F-FDG亲和性、SUVmax、局灶性病变数目、旁髓病变(PMD)或髓外病变的存在。
  • 对同一批患者分选骨髓浆细胞行RNA测序转录组分析,并探索与高危基因表达签名(IFM15)、分子分型、无进展生存期、严格临床缓解及微小残留病阴性的关联。

主要发现

  • 18F-FDG PET结果阳性者占79.4%,其中旁髓病变和髓外病变分别占14%和11%。
  • 18F-FDG PET阴性结果与己糖激酶2(HK2)表达较低相关(倍数变化2.1,校正P=0.04),并富集低骨病负荷患者亚组。
  • 18F-FDG PET阳性结果呈现两种不同签名:增殖基因高表达,或GLUT5与淋巴细胞抗原高表达。
  • 旁髓病变与IFM15均独立关联无进展生存期降低,两者并存定义进展风险极高的双阳性患者组。
  • 旁髓病变与IFM15均与微小残留病评估及严格临床缓解无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The International Myeloma Working Group recently fully incorporated 18F-FDG PET into multiple myeloma (MM) diagnosis and response evaluation. Moreover, a few studies demonstrated the prognostic value of several biomarkers extracted from this imaging at baseline. Before these 18F-FDG PET biomarkers could be fully endorsed as risk classifiers by the hematologist community, further characterization of underlying molecular aspects was necessary. Methods: Reported prognostic biomarkers (18F-FDG avidity, SUVmax, number of focal lesions, presence of paramedullary disease [PMD] or extramedullary disease) were extracted from 18F-FDG PET imaging at baseline in a group of 139 patients from CASSIOPET, a companion study of the CASSIOPEIA cohort (ClinicalTrials.gov identifier NCT02541383). Transcriptomic analyses using RNA sequencing were realized on sorted bone marrow plasma cells from the same patients. An association with a high-risk gene expression signature (IFM15), molecular classification, progression-free survival, a stringent clinical response, and minimal residual disease negativity were explored. Results:18F-FDG PET results were positive in 79.4% of patients; 14% and 11% of them had PMD and extramedullary disease, respectively. Negative 18F-FDG PET results were associated with lower levels of expression of hexokinase 2 (HK2) (fold change, 2.1; adjusted P = 0.04) and showed enrichment for a subgroup of patients with a low level of bone disease. Positive 18F-FDG PET results displayed 2 distinct signatures: either high levels of expression of proliferation genes or high levels of expression of GLUT5 and lymphocyte antigens. PMD and IFM15 were independently associated with a lower level of progression-free survival, and the presence of both biomarkers defined a group of "double-positive" patients at very high risk of progression. PMD and IFM15 were related neither to minimal residual disease assessment nor to a stringent clinical response. Conclusion: Our study confirmed and extended the association between imaging biomarkers and transcriptomic programs in MM. The combined prognostic value of PMD and a high-risk IFM15 signature may help define MM patients with a very high risk of progression.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Alberge JB, Kraeber-Bodéré F, Jamet B, et al. Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. J Nucl Med. 2022. PMID: 35086897. doi:10.2967/jnumed.121.262884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。